KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma
- 6 April 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (8), 526-535
- https://doi.org/10.1016/j.clml.2021.03.013
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studiesHaematologica, 2013
- D(T)PACE as salvage therapy for aggressive or refractory multiple myelomaBritish Journal of Haematology, 2013
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyBlood, 2012
- Multiple myeloma: 2012 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2011
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse EventsClinical Cancer Research, 2011
- Multiple MyelomaThe New England Journal of Medicine, 2011
- Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesLeukemia & Lymphoma, 2010
- Many facets of bortezomib resistance/susceptibilityBlood, 2008
- Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3British Journal of Haematology, 2007
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005